Heart Drug Developer Kardigan Files IPO

Deal Summary

Cardiovascular drug developer Kardigan announced it has filed for an initial public offering on the Nasdaq under the ticker KARD. The company, which previously raised $254 million in a Series B and $300 million in a prior round, aims to raise additional capital to fund late‑stage trials for its three heart‑focused drug candidates. The IPO valuation and pricing were not disclosed.